Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Cholangiocarcinoma 4Stomach Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced and Metastatic Urothelial Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced and Metastatic Urothelial Cancer × futibatinib × Clear all
NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Taiho Oncology, Inc.

Phase 2 Terminated
43 enrolled 15 charts
Genitourinary

Advanced and Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡